A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This is a 24-week study to evaluate the efficacy and safety of a once-daily ritonavir-boosted
fosamprenavir regimen (1400mg/100mg QD) to a 200mg ritonavir-boosted fosamprenavir regimen
administered either twice-daily or once-daily.